Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024

Core Insights - Aileron Therapeutics is hosting a virtual key opinion leader event focused on treating Idiopathic Pulmonary Fibrosis on February 15, 2024 [1] - The event will feature discussions on emerging therapies, particularly Aileron's lead product candidate, LTI-03, which targets alveolar epithelial cell survival and inhibits profibrotic signaling [1][3] - Aileron's LTI-03 is currently in a Phase 1b clinical trial, with topline results expected by the end of Q2 2024 [3] Company Overview - Aileron Therapeutics is a biopharmaceutical company developing first-in-class medicines for orphan pulmonary and fibrosis indications [3] - The company’s second product candidate, LTI-01, has completed Phase 1b and Phase 2a clinical trials and has received Orphan Drug Designation in the US and EU, as well as Fast Track Designation in the US [3]